Vistagen Therapeutics Inc
For the period ended Mar 31, 2025. Filed Jun 17, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Jun 17, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused
this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Vistagen Therapeutics, Inc. | ||
| Date: June 17, 2025 | By: | /s/ Shawn K. Singh |
|---|---|---|
| Shawn K. Singh, J.D.President and Chief Executive Officer | ||
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following
persons on behalf of the registrant and in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Shawn K. Singh | President and Chief Executive Officer and Director | June 17, 2025 |
| Shawn K. Singh, J.D. | (Principal Executive Officer) | |
| /s/ Cynthia L. Anderson | Chief Financial Officer and Treasurer | June 17, 2025 |
| Cynthia L. Anderson, CPA | (Principal Financial and Accounting Officer) | |
| /s/ Margaret M. FitzPatrick | Chair of the Board of Directors | June 17, 2025 |
| Margaret M. FitzPatrick | ||
| /s/ Ann M. Cunningham | Director | June 17, 2025 |
| Ann M. Cunningham | ||
| /s/ Joanne Curley | Director | June 17, 2025 |
| Joanne Curley, Ph.D. | ||
| /s/ Jerry B. Gin | Director | June 17, 2025 |
| Jerry B. Gin, Ph.D. | ||
| /s/ Mary L. Rotunno | Director | June 17, 2025 |
| Mary L. Rotunno, J.D. | ||
| /s/ Jon S. Saxe | Director | June 17, 2025 |
| Jon S. Saxe, J.D., LL.M. | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.